AbCellera to present Phase 1/2 data for menopause hot-flash drug ABCL635 at TMS 2026 meeting
Bitget2026/10/08 20:06AbCellera flagged Phase 1/2 findings for ABCL635, a non-hormonal antibody aimed at menopausal hot flashes. Results have not been presented yet; data are scheduled for a poster at The Menopause Society’s 2026 annual meeting on Oct. 22. Readout supports continued development, based on reported safety, drug exposure, biological activity, and early signs of symptom improvement. The program targets NK3R, positioning ABCL635 as a long-acting approach in a competitive market for vasomotor symptom treatments. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261008273252) on October 08, 2026, and is solely responsible for the information contained therein.
- AbCellera flagged Phase 1/2 findings for ABCL635, a non-hormonal antibody aimed at menopausal hot flashes.
- Results have not been presented yet; data are scheduled for a poster at The Menopause Society’s 2026 annual meeting on Oct. 22.
- Readout supports continued development, based on reported safety, drug exposure, biological activity, and early signs of symptom improvement.
- The program targets NK3R, positioning ABCL635 as a long-acting approach in a competitive market for vasomotor symptom treatments.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canadian used car dealer UC Automotive (UCAU.RC.US) files for IPO in the US: aims to raise 29 million USD and list on Nasdaq
Canadian used car dealer UC Automotive has applied for a Nasdaq IPO, aiming to raise up to $29 million, with its main focus on the Greater Vancouver market. Kingswood is the sole underwriter.
Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF
Crypto prices
More
